GigaGen, a subsidiary of Grifols, has announced the commencement of a Phase I clinical trial evaluating GIGA-2339, an innovative recombinant polyclonal antibody drug candidate for the treatment of chronic hepatitis B virus (HBV) infection. The first patient has been dosed in this dose-escalation study, which aims to determine the safety and tolerability of GIGA-2339 in individuals with confirmed chronic HBV.
Novel Approach to HBV Treatment
GIGA-2339 is composed of over 1,000 distinct anti-HBV antibodies, bioengineered to mirror the natural antibody response observed in vaccinated individuals. According to GigaGen, this approach results in a drug with potency more than 2,000 times greater than traditional plasma-derived HBV treatments, offering a broad spectrum of coverage against various HBV variants.
Preclinical Evidence
Preclinical studies conducted in mouse models have demonstrated that GIGA-2339 can effectively neutralize and eliminate HBV viral antigens and deoxyribonucleic acid (DNA). This unique mechanism of action has the potential to clear viral particles and stimulate the immune system, potentially leading to a functional cure for individuals living with chronic HBV.
Management Perspective
"The initiation of this Phase I trial with GIGA-2339 represents a milestone in our mission to develop the next generation of antibody drugs for addressing infectious disease treatment," said Carter Keller, GigaGen head and Grifols senior vice-president. "By harnessing the precision of these antibodies, it targets the large diversity of circulating HBV variants, offering a more targeted and effective solution with potential to bring new hope to millions affected by this chronic disease."
Trial Design and Objectives
The Phase I trial is designed as a dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GIGA-2339 in patients with chronic HBV infection. Further details regarding the trial design, patient population, and specific endpoints were not disclosed in the announcement.
